Plato Investment Management Ltd Buys 44 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Plato Investment Management Ltd lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,661 shares of the biopharmaceutical company’s stock after acquiring an additional 44 shares during the period. Plato Investment Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $1,902,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Bellecapital International Ltd. boosted its stake in Regeneron Pharmaceuticals by 44.1% during the fourth quarter. Bellecapital International Ltd. now owns 19,600 shares of the biopharmaceutical company’s stock valued at $13,962,000 after buying an additional 6,002 shares during the period. SBI Securities Co. Ltd. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $464,000. Jones Financial Companies Lllp boosted its stake in Regeneron Pharmaceuticals by 107.7% during the fourth quarter. Jones Financial Companies Lllp now owns 812 shares of the biopharmaceutical company’s stock valued at $578,000 after buying an additional 421 shares during the period. Bailard Inc. boosted its stake in Regeneron Pharmaceuticals by 10.1% during the fourth quarter. Bailard Inc. now owns 13,422 shares of the biopharmaceutical company’s stock valued at $9,561,000 after buying an additional 1,236 shares during the period. Finally, Smartleaf Asset Management LLC boosted its stake in Regeneron Pharmaceuticals by 8.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 952 shares of the biopharmaceutical company’s stock valued at $669,000 after buying an additional 72 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 2.0 %

Shares of NASDAQ:REGN opened at $684.87 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a market cap of $74.87 billion, a PE ratio of 17.89, a P/E/G ratio of 2.34 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock’s 50-day moving average is $697.91 and its 200 day moving average is $862.68.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the previous year, the business earned $11.86 EPS. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.51%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on REGN. Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Citigroup dropped their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Oppenheimer dropped their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. Finally, StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.